Kala Pharmaceuticals, Inc. (0JQ2.L)

USD 6.03

(-3.51%)

Revenue Summary of Kala Pharmaceuticals, Inc.

  • Kala Pharmaceuticals, Inc.'s latest annual revenue in 2023 was - USD , down -100.0% from previous year.
  • Kala Pharmaceuticals, Inc.'s latest quarterly revenue in 2024 Q2 was - USD , down 0.0% from previous quarter.
  • Kala Pharmaceuticals, Inc. reported a annual revenue of 3.89 Million USD in annual revenue 2022, down -65.37% from previous year.
  • Kala Pharmaceuticals, Inc. reported a annual revenue of 11.24 Million USD in annual revenue 2021, up 76.67% from previous year.
  • Kala Pharmaceuticals, Inc. reported a quarterly revenue of - USD for 2024 Q2, down 0.0% from previous quarter.
  • Kala Pharmaceuticals, Inc. reported a quarterly revenue of - USD for 2023 Q1, down -100.0% from previous quarter.

Annual Revenue Chart of Kala Pharmaceuticals, Inc. (2023 - 2015)

Historical Annual Revenue of Kala Pharmaceuticals, Inc. (2023 - 2015)

Year Revenue Revenue Growth
2023 - USD -100.0%
2022 3.89 Million USD -65.37%
2021 11.24 Million USD 76.67%
2020 6.36 Million USD 4.74%
2019 6.07 Million USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD -100.0%
2015 45 Thousand USD 0.0%

Peer Revenue Comparison of Kala Pharmaceuticals, Inc.

Name Revenue Revenue Difference
Editas Medicine, Inc. 78.12 Million USD 100.0%
Dynavax Technologies Corporation 232.28 Million USD 100.0%
Supernus Pharmaceuticals, Inc. 607.52 Million USD 100.0%
Perrigo Company plc 4.65 Billion USD 100.0%
Illumina, Inc. 4.5 Billion USD 100.0%
Thermo Fisher Scientific Inc. 42.85 Billion USD 100.0%
Iovance Biotherapeutics, Inc. 1.18 Million USD 100.0%
Walgreens Boots Alliance, Inc. 147.65 Billion USD 100.0%
IQVIA Holdings Inc. 14.98 Billion USD 100.0%
Heron Therapeutics, Inc. 127.04 Million USD 100.0%
Regeneron Pharmaceuticals, Inc. 13.11 Billion USD 100.0%
Unity Biotechnology, Inc. - USD NaN%
Waters Corporation 2.95 Billion USD 100.0%
Biogen Inc. 9.83 Billion USD 100.0%
Sangamo Therapeutics, Inc. 176.23 Million USD 100.0%
Evolus, Inc. 202.08 Million USD 100.0%
Adicet Bio, Inc. - USD NaN%
Cara Therapeutics, Inc. 20.96 Million USD 100.0%
bluebird bio, Inc. 29.49 Million USD 100.0%
Esperion Therapeutics, Inc. 116.33 Million USD 100.0%
FibroGen, Inc. 147.75 Million USD 100.0%
Agilent Technologies, Inc. 6.83 Billion USD 100.0%
Corbus Pharmaceuticals Holdings, Inc. - USD NaN%
Homology Medicines, Inc. -6.65 Million USD 100.0%
Geron Corporation 237 Thousand USD 100.0%
Alnylam Pharmaceuticals, Inc. 1.82 Billion USD 100.0%
Amicus Therapeutics, Inc. 399.35 Million USD 100.0%
Myriad Genetics, Inc. 678.4 Million USD 100.0%
Viking Therapeutics, Inc. - USD NaN%
Intellia Therapeutics, Inc. 36.27 Million USD 100.0%
Zoetis Inc. 8.54 Billion USD 100.0%
Abeona Therapeutics Inc. 3.5 Million USD 100.0%
Mettler-Toledo International Inc. 3.78 Billion USD 100.0%
BioMarin Pharmaceutical Inc. 2.41 Billion USD 100.0%
Vertex Pharmaceuticals Incorporated 9.86 Billion USD 100.0%
Ionis Pharmaceuticals, Inc. 787.64 Million USD 100.0%
Atara Biotherapeutics, Inc. 8.57 Million USD 100.0%
Verastem, Inc. - USD NaN%
Nektar Therapeutics 90.12 Million USD 100.0%
Axsome Therapeutics, Inc. 270.6 Million USD 100.0%
Aclaris Therapeutics, Inc. 31.24 Million USD 100.0%
Sarepta Therapeutics, Inc. 1.24 Billion USD 100.0%
OPKO Health, Inc. 863.49 Million USD 100.0%
Exelixis, Inc. 1.83 Billion USD 100.0%
Neurocrine Biosciences, Inc. 1.88 Billion USD 100.0%
Corcept Therapeutics Incorporated 482.37 Million USD 100.0%
Anavex Life Sciences Corp. - USD NaN%
uniQure N.V. 15.84 Million USD 100.0%
Imunon, Inc. - USD NaN%
Blueprint Medicines Corporation 249.38 Million USD 100.0%
Insmed Incorporated 305.2 Million USD 100.0%
Halozyme Therapeutics, Inc. 829.25 Million USD 100.0%
Agios Pharmaceuticals, Inc. 26.82 Million USD 100.0%
TG Therapeutics, Inc. 233.66 Million USD 100.0%
Incyte Corporation 3.69 Billion USD 100.0%
Emergent BioSolutions Inc. 1.04 Billion USD 100.0%